NDC 70771-1015 Nateglinide

Nateglinide

NDC Product Code 70771-1015

NDC CODE: 70771-1015

Proprietary Name: Nateglinide What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Nateglinide What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • Nateglinide is used alone or with other medications to control high blood sugar along with a proper diet and exercise program. It is used in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. It works by stimulating the body to produce more insulin. Insulin is a natural substance that allows the body to properly use sugar from the diet.

Product Characteristics

Color(s):
WHITE (C48325 - WHITE TO OFF-WHITE)
Shape: ROUND (C48348)
Size(s):
10 MM
Imprint(s):
721
Score: 1

NDC Code Structure

NDC 70771-1015-0

Package Description: 1000 TABLET, FILM COATED in 1 BOTTLE

NDC 70771-1015-1

Package Description: 100 TABLET, FILM COATED in 1 BOTTLE

NDC 70771-1015-3

Package Description: 30 TABLET, FILM COATED in 1 BOTTLE

NDC 70771-1015-4

Package Description: 10 BLISTER PACK in 1 CARTON > 10 TABLET, FILM COATED in 1 BLISTER PACK (70771-1015-2)

NDC 70771-1015-5

Package Description: 500 TABLET, FILM COATED in 1 BOTTLE

NDC 70771-1015-9

Package Description: 90 TABLET, FILM COATED in 1 BOTTLE

NDC Product Information

Nateglinide with NDC 70771-1015 is a a human prescription drug product labeled by Cadila Healthcare Limited. The generic name of Nateglinide is nateglinide. The product's dosage form is tablet, film coated and is administered via oral form.

Labeler Name: Cadila Healthcare Limited

Dosage Form: Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Nateglinide Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • NATEGLINIDE 60 mg/1

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
  • SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
  • STARCH, CORN (UNII: O8232NY3SJ)
  • CROSPOVIDONE (UNII: 2S7830E561)
  • HYPROMELLOSES (UNII: 3NXW29V3WO)
  • LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
  • MAGNESIUM STEARATE (UNII: 70097M6I30)
  • POLYSORBATE 80 (UNII: 6OZP39ZG8H)
  • POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)
  • POVIDONE (UNII: FZ989GH94E)
  • TALC (UNII: 7SEV7J4R1U)
  • TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Glinide - [EPC] (Established Pharmacologic Class)
  • Potassium Channel Antagonists - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Cadila Healthcare Limited
Labeler Code: 70771
FDA Application Number: ANDA205248 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 10-27-2016 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients

Nateglinide Oral

Nateglinide Oral is pronounced as (nuh tay' gli nide)

Why is nateglinide oral medication prescribed?
Nateglinide is used alone or in combination with other medications to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore canno...
[Read More]

* Please review the disclaimer below.

Nateglinide Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Limitations of Use:Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

2 Dosage And Administration

The recommended dose of nateglinide tablets is 120 mg orally three times daily before meals.The recommended dose of nateglinide tablets is 60 mg orally three times daily before meals in patients who are near glycemic goal when treatment is initiated.Instruct patients to take nateglinide tablets is 1 to 30 minutes before meals.In patients who skip meals, instruct patients to skip the scheduled dose of nateglinide tablets to reduce the risk of hypoglycemia [see Warnings and Precautions (5.1)].

3 Dosage Forms And Strengths

  • Nateglinide Tablets USP, 60 mg are white to off-white, round, biconvex with bevel-edge, film-coated tablets debossed '721' on one side and plain on the other side.Nateglinide Tablets USP, 120 mg are light-orange to orange, oval, biconvex with bevel-edge, film-coated tablets debossed '722' on one side and plain on the other side.

4 Contraindications

Nateglinide is contraindicated in patients with a history of hypersensitivity to nateglinide or its active ingredients.

5.1 Hypoglycemia

All glinides, including nateglinide, can cause hypoglycemia [see Adverse Reactions (6.1)]. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy (nerve disease), in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia.Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content), changes in level of physical activity, changes to coadministered medication [see Drug Interactions (7)], and concomitant use with other antidiabetic agents. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].Patients should take nateglinide before meals and be instructed to skip the dose of nateglinide if a meal is skipped [see Dosage and Administration (2)]. Patients and caregivers must be educated to recognize and manage hypoglycemia. Self- monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.

5.2 Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with nateglinide.

6 Adverse Reactions

The following serious adverse reaction is also described elsewhere in the labeling:Hypoglycemia [see Warnings and Precautions (5.1)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In clinical trials, approximately 2,600 patients with type 2 diabetes mellitus were treated with nateglinide. Of these, approximately 1,335 patients were treated for 6 months or longer and approximately 190 patients for one year or longer. Table 1 shows the most common adverse reactions associated with nateglinide. Table 1 Adverse Reactions other than Hypoglycemia (%) occurring ≥ 2% in Nateglinide-Treated Patients from Pool of 12 to 64 week Placebo Controlled Trials Placebo NateglinideN=458N=1,441 Preferred Term Upper Respiratory Infection 8.1 10.5 Back Pain 3.7 4 Flu Symptoms 2.6 3.6 Dizziness 2.2 3.6 Arthropathy 2.2 3.3 Diarrhea 3.1 3.2 Accidental Trauma 1.7 2.9 Bronchitis 2.6 2.7 Coughing 2.2 2.4HypoglycemiaEpisodes of severe hypoglycemia (plasma glucose less than 36 mg/dL) were reported in two patients treated with nateglinide. Non-severe hypoglycemia occurred in 2.4 % of nateglinide treated patients and 0.4 % of placebo treated patients [see Warnings and Precautions (5.1)].Weight GainPatients treated with nateglinide had statistically significant mean increases in weight compared to placebo. In clinical trials, the mean weight increases with nateglinide 60 mg (3 times daily) and nateglinide 120 mg (3 times daily) compared to placebo were 1kg and 1.6 kg respectively.Laboratory TestIncreases in Uric Acid: There were increases in mean uric acid levels for patients treated with nateglinide alone, nateglinide in combination with metformin, metformin alone, and glyburide alone. The respective differences from placebo were 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL.

6.2 Postmarketing Experience

  • The following adverse reactions have been identified during post-approval use of nateglinide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Hypersensitivity reactions: Rash, itching, and urticariaHepatobiliary Disorders: Jaundice, cholestatic hepatitis, and elevated liver enzymes

7 Drug Interactions

Table 2 includes a list of drugs with clinically important drug interactions when concomitantly administered or withdrawn with nateglinide and instructions for managing or preventing them. Table 2 Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to HypoglycemiaDrugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g. methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g. amiodarone, fluconazole, voriconazole, sulfinpyrazone), alcohol.Intervention: Dose reductions and increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs. Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to HyperglycemiaDrugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g. lanreotide, octreotide), and CYP inducers (e.g. rifampin, phenytoin and St John's Wort).Intervention: Dose increases and increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs. Drugs That May Blunt Signs and Symptoms of HypoglycemiaDrugs: beta-blockers, clonidine, guanethidine, and reserpineIntervention: Increased frequency of glucose monitoring may be required when nateglinide is co-administered with these drugs.

8.1 Pregnancy

Pregnancy Category CThere are no adequate and well-controlled studies of nateglinide in pregnant women. It is unknown whether nateglinide can cause fetal harm when administered to a pregnant woman. Nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.In the rabbit, embryonic development was adversely affected and the incidence of gall bladder agenesis or small gallbladder was increased at a dose of 500 mg/kg (approximately 27 times the human therapeutic exposure of 120 mg three times daily, based on body surface area). Nateglinide was not teratogenic in rats at doses up to 1,000 mg/kg (approximately 27 times the human therapeutic exposure based on body surface area).

8.3 Nursing Mothers

It is not known whether nateglinide is excreted in human milk. Nateglinide is excreted in rat milk. Offspring of rats exposed to 1,000 mg/kg nateglinide (approximately 27 times the human therapeutic exposure of 120 mg three times daily, based on body surface area) had lower body weight. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made as to whether nateglinide should be discontinued in nursing mothers, or if mothers should discontinue nursing.

8.4 Pediatric Use

The safety and effectiveness of nateglinide have not been established in pediatric patients.

8.5 Geriatric Use

436 patients 65 years and older, and 80 patients 75 years and older were exposed to nateglinide in clinical studies. No differences were observed in safety or efficacy of nateglinide between patients age 65 and over, and those under age 65. However, greater sensitivity of some older individuals to nateglinide therapy cannot be ruled out.

8.6 Renal Impairment

No dosage adjustment is recommended in patients with mild to severe renal impairment [see Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

No dose adjustment is recommended for patients with mild hepatic impairment. Use of nateglinide in patients with moderate-to-severe hepatic impairment has not been studied and therefore, should be used with caution in these patients [see Clinical Pharmacology (12.3)].

10 Overdosage

There have been no instances of overdose with nateglinide in clinical trials. However, an overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms. Hypoglycemic symptoms without loss of consciousness or neurological findings should be treated with oral glucose and adjustments in dosage and/or meal patterns. Severe hypoglycemic reactions with coma, seizure, or other neurological symptoms should be treated with intravenous glucose. As nateglinide is highly protein bound, dialysis is not an efficient means of removing it from the blood.

11 Description

Nateglinide is an oral blood glucose-lowering drug of the glinide class. Nateglinide, (-)-N-[(trans-4- isopropylcyclohexane)carbonyl]-D-phenylalanine, is structurally unrelated to the oral sulfonylurea insulin secretagogues.The structural formula is as shown:Nateglinide, USP is a white powder with a molecular weight of 317.43. It is freely soluble in methanol and alcohol, soluble in ether, sparingly soluble in acetonitrile and octanol, practically insoluble in water.Each nateglinide tablet, USP intended for oral administration contains nateglinide, USP 60 mg and 120 mg. In addition, each tablet contains the following inactive ingredients: citric acid anhydrous, colloidal silicon dioxide, corn starch, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, polysorbate 80, polyethylene glycol, povidone, talc and titanium dioxide. Additionally, each 120 mg tablet contains iron oxide red and iron oxide yellow.

12.1 Mechanism Of Action

Nateglinide lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets. Nateglinide interacts with the ATP-sensitive potassium (K+ATP) channel on pancreatic beta-cells. The subsequent depolarization of the beta cell opens the calcium channel, producing calcium influx and insulin secretion. The extent of insulin release is glucose dependent and diminishes at low glucose levels. Nateglinide is highly tissue selective with low affinity for heart and skeletal muscle.

12.2 Pharmacodynamics

Nateglinide stimulates pancreatic insulin secretion within 20 minutes of oral administration. When nateglinide is dosed before meals, the peak rise in plasma insulin occurs approximately 1 hour after dosing and falls to baseline by 4 hours after dosing.

12.3 Pharmacokinetics

In patients with Type 2 diabetes, multiple dose administration of nateglinide over the dosage range of 60 mg to 240 mg shows linear pharmacokinetics for both AUC and Cmax. In patients with Type 2 diabetes, there is no apparent accumulation of nateglinide upon multiple dosing of up to 240 mg three times daily for 7 days.AbsorptionAbsolute bioavailability of nateglinide is approximately 73%. Plasma profiles are characterized by multiple plasma concentration peaks when nateglinide is administered under fasting conditions. This effect is diminished when nateglinide is taken prior to a meal. Following oral administration immediately prior to a meal, the mean peak plasma nateglinide concentrations (Cmax) generally occur within 1 hour (Tmax) after dosing. Tmax is independent of dose.The pharmacokinetics of nateglinide are not affected by the composition of a meal (high protein, fat, or carbohydrate). However, peak plasma levels are significantly reduced when nateglinide is administered 10 minutes prior to a liquid meal as compared to solid meal. When given with or after meals, the extent of nateglinide absorption (AUC) remains unaffected. However, there is a delay in the rate of absorption characterized by a decrease in Cmax and a delay in time to peak plasma concentration (Tmax).Nateglinide tablets did not have any effect on gastric emptying in healthy subjects as assessed by acetaminophen testing. DistributionFollowing intravenous (IV) administration of nateglinide, the steady-state volume of distribution of nateglinide is estimated to be approximately 10 L in healthy subjects. Nateglinide is extensively bound (98%) to serum proteins, primarily serum albumin, and to a lesser extent α1 acid glycoprotein. The extent of serum protein binding is independent of drug concentration over the test range of 0.1 to 10 mcg/mL.EliminationIn healthy volunteers and patients with type 2 diabetes mellitus, nateglinide plasma concentrations declined with an average elimination half-life of approximately 1.5 hours.MetabolismIn vitro drug metabolism studies indicate that nateglinide is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).The major routes of metabolism are hydroxylation followed by glucuronide conjugation. The major metabolites are less potent antidiabetic agents than nateglinide. The isoprene minor metabolite possesses potency similar to that of the parent compound nateglinide.ExcretionNateglinide and its metabolites are rapidly and completely eliminated following oral administration. Eighty-three percent of the 14C-nateglinide was excreted in the urine with an additional 10% eliminated in the feces. Approximately 16% of the 14C -nateglinide was excreted in the urine as parent compound.Specific PopulationsRenal ImpairmentNo pharmacokinetic data are available in subjects with mild renal impairment (CrCl 60 to 89 mL/min). Compared to healthy matched subjects, patients with type 2 diabetes mellitus and moderate and severe renal impairment (CrCl 15 mL/min to 50 mL/min) not on dialysis displayed similar apparent clearance, AUC, and Cmax. Patients with type 2 diabetes and renal failure on dialysis exhibited reduced overall drug exposure (Cmax decreased by 49%; not statistically significant). However, hemodialysis patients also experienced reductions in plasma protein binding compared to the matched healthy volunteers.Hepatic ImpairmentIn patients with mild hepatic impairment, the mean increase in Cmax and AUC of nateglinide were 37% and 30 % respectively, as compared to healthy matched control subjects. There is no data on pharmacokinetics of nateglinide in patients with moderate-to-severe hepatic impairment.GenderNo clinically significant differences in nateglinide pharmacokinetics were observed between men and women.RaceResults of a population pharmacokinetic analysis including subjects of Caucasian, Black, and other ethnic origins suggest that race has little influence on the pharmacokinetics of nateglinide.AgeAge does not influence the pharmacokinetic properties of nateglinide.Drug Interactions:In vitro assessment of drug interactionsNateglinide is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide. Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding. Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro. However, prudent evaluation of individual cases is warranted in the clinical setting.In vivo assessment of drug interactionsThe effect of coadministered drugs on the pharmacokinetics of nateglinide and the effect of nateglinide on pharmacokinetics of coadministered drugs are shown in Tables 3 and 4. No clinically relevant change in pharmacokinetic parameters of either agent was reported when nateglinide was coadministered with glyburide, metformin, digoxin, warfarin, and diclofenac. Table 3 Effect of Coadministered drugs on Pharmacokinetics of Nateglinide Coadministered drug Dosing regimen of coadministered drug Dosing regimen of nateglinide Change in Cmax Change in AUC Glyburide 10 mg once daily for 3 weeks 120 mg three times a day, single dose 8.78% ↓ 3.53 % ↓ Metformin 500 mg three times a day for 3 weeks 120 mg three times a day, single dose AM: 7.14% ↑ PM: 11.4% ↓ AM: 1.51% ↑ PM: 5.97% ↑ Digoxin 1 mg, single dose 120 mg three times a day, single dose AM: 2.17% ↓ PM: 3.19% ↑ AM: 7.62% ↑ PM: 2.22% ↑ Warfarin 30 mg, single dose 120 mg three times a day for 4 days 2.65% ↑ 3.72% ↓ Diclofenac 75 mg, single dose 120 mg twice daily, single dose AM: 13.23% ↓ *PM: 3.76% ↑ AM: 2.2% ↓ *PM: 7.5% ↑AM: after morning dose; PM: after evening dose; * after second dose; ↑: increase in the parameter; ↓: decrease in the parameter Table 4 Effect of Nateglinide on Pharmacokinetics of Coadministered Drugs Coadministered drug Dosing regimen of coadministered drug Dosing regimen of nateglinide Change in Cmax Change in AUC Glyburide 10 mg once daily for 3 weeks 120 mg three times a day, single dose 3.18% ↓ 7.34 % ↓ Metformin 500 mg three times a day for 3 weeks 120 mg three times a day, single dose AM: 10.7% ↑ PM: 0.40% ↓ AM: 13.3% ↑ PM: 2.27% ↓ Digoxin 1 mg, single dose 120 mg three times a day, single dose 5.41% ↓ 6.58% ↑ Warfarin 30 mg, single dose 120 mg three times a day for 4 days R-Warfarin: 1.03%↓ S-Warfarin: 0.85%↓ R-Warfarin: 0.74%↑ S-Warfarin: 7.23%↑ Diclofenac 75 mg, single dose 120 mg twice daily, single dose 2.19% ↑ 7.97% ↑AM: after morning dose; PM: after evening dose; SD: single dose; ↑: increase in the parameter; ↓: decrease in the parameter

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

Carcinogenicity: Nateglinide did not increase tumors in two year carcinogenicity studies conducted in mice and rats. Oral doses of Nateglinide up to 900 mg/kg in rats and 400 mg/kg in mice were tested, which produced exposures in rats approximately 30 times to 40 times and in mice 10 times to 30 times the human therapeutic exposure of nateglinide at a dose of 120 mg three times daily, based on AUC.Mutagenesis: Nateglinide was not genotoxic in the in vitro Ames test, mouse lymphoma assay, chromosome aberration assay or in the in vivo mouse micronucleus test.Impairment of Fertility:  Fertility was unaffected by administration of nateglinide to rats at doses up to 600 mg/kg (approximately 16 times the human therapeutic exposure with a recommended nateglinide dose of 120 mg three times daily before meals).

14.1 Monotherapy

In a 24-week, double-blind, placebo-controlled study, patients with type 2 diabetes were randomized to receive either nateglinide (60 mg or 120 mg three times daily before meals) or placebo.  Patients previously treated with antidiabetic medications were required to discontinue that medication for at least 2 months before randomization.At Week 24, treatment with nateglinide before meals resulted in statistically significant reductions in mean HbA1C and mean fasting plasma glucose (FPG) compared to placebo (see Table 5). The reductions in HbA1C and FPG were similar for patients naïve to, and those previously exposed to, antidiabetic medications. Table 5 Endpoint results for a 24-week, fixed dose study of Nateglinide monotherapy Placebo Nateglinide Nateglinide 60 mg 120 mg three times daily before meals three times daily before meals HbA1C (%)N=168N=167N=168 Baseline (mean) 8.0 7.9 8.1 Change from baseline (mean) +0.2 -0.3 -0.5 Difference from placebo (mean) -0.5a -0.7a FPG (mg/dL)N=172N=171N=169 Baseline (mean) 167.9 161.0 166.5 Change from baseline (mean) +9.1 +0.4 -4.5 Difference from placebo (mean) -8.7a -13.6aap-value ≤ 0.004

14.2 Monotherapy Compared To Glyburide

In a 24-week, double-blind, active-controlled trial, patients with type 2 diabetes who had been on a sulfonylurea for 3 or more months and who had a baseline HbA1C greater than or equal to 6.5% were randomized to receive nateglinide (60 mg or 120 mg three times daily before meals) or glyburide 10 mg once daily. Patients randomized to nateglinide had significant increases in mean HbA1C and mean FPG at endpoint compared to patients randomized to glyburide. Table 6 Endpoint results for a 24-week study of Nateglinide monotherapy compared to glyburide a p-value <0.001 Glyburide Nateglinide Nateglinide 10 mg 60 mg 120 mg Once daily three times daily before meals three times daily before meals HbA1C (%)N=183N=178N=179 Baseline (mean) 7.8 8.0 7.9 Change from baseline (mean) 0.3 1.3 1.1 Difference from glyburide (mean) 1a 0.9a FPG (mmol/L)N=184N=182N=180 Baseline (mean) 9.44 9.67 9.61 Change from baseline (mean) 0.19 3.06 2.84 Difference from glyburide (mean) 2.87a 2.66a

14.3 Monotherapy And In Combination With Metformin

In a 24-week, double-blind, active- and placebo-controlled study, patients with type 2 diabetes were randomized to receive either nateglinide alone (120 mg three times daily before meals), metformin alone (500 mg three times daily), a combination of nateglinide 120 mg (three times daily before meals) and metformin (500 mg three times daily), or placebo. Fifty-seven percent of patients were previously untreated with oral antidiabetic therapy. Patients previously treated with antidiabetic medications were required to discontinue medication for at least 2 months before randomization.At Week 24, statistically significant reductions in mean HbA1c and FPG were observed with metformin monotherapy compared to nateglinide monotherapy, and the combination of nateglinide and metformin compared to either nateglinide or metformin monotherapy (see Table 7).Compared to placebo, nateglinide monotherapy was associated with a statistically significant increase in mean body weight, while no significant change in body weight was observed with metformin monotherapy or combination of nateglinide and metformin therapy (see Table 7). Among the subset of patients previously treated with other antidiabetic agents, primarily glyburide, HbA1C in the nateglinide monotherapy group increased slightly from baseline, whereas HbA1C was reduced in the metformin monotherapy group (see Table 7). Table 7 Endpoint results for a 24-week study of Nateglinide monotherapy and combination with metformin ap-value ≤ 0.05 vs. placebobp-value ≤ 0.03 vs. metformincp-value ≤ 0.05 vs. combination* Metformin was administered three times daily Placebo Nateglinide Metformin Nateglinide 120 mg 500 mg 120 mg three times daily before meals three times daily before meals plus Metformin* HbA1C (%) AllN=160N=171N=172N=162 Baseline (mean) 8.3 8.3 8.4 8.4 Change from baseline (mean) +0.4 -0.4bc -0.8c -1.5 Difference from placebo -0.8a -1.2a -1.9a NaїveN=98N=99N=98N=81 Baseline (mean) 8.2 8.1 8.3 8.2 Change from baseline (mean) +0.3 -0.7c -0.8c -1.6 Difference from placebo -1a -1.1a -1.9a Non- NaїveN=62N=72N=74N=81 Baseline (mean) 8.3 8.5 8.7 8.7 Change from baseline (mean) +0.6 +0.004bc -0.8c -1.4 Difference from placebo -0.6a -1.4a -2a FPG (mg/dL) AllN=166N=173N=174N=167 Baseline (mean) 194 196.5 196 197.7 Change from baseline (mean) +8 -13.1bc -30c -44.9 Difference from placebo -21.1a -38a -52.9aIn another 24-week, double-blind, placebo-controlled trial, patients with type 2 diabetes with HbA1C greater than or equal to 6.8% after treatment with metformin (greater than or equal to 1,500 mg daily for at least 1 month) were first entered into a four week run-in period of metformin monotherapy (2,000 mg daily) and then randomized to receive either nateglinide (60 mg or 120 mg three times daily before meals) or placebo as add-on to metformin. At the end of treatment, nateglinide 60 mg and 120 mg three times daily resulted in a statistically significantly greater reductions in HbA1C compared to placebo when added to metformin (-0.4% and -0.6% for nateglinide 60 mg and nateglinide 120 mg plus metformin, respectively). Table 8 Endpoint results for a 24-week study of Nateglinide monotherapy as add-on to metformin a p-value 0.003 vs. metforminb p-value < 0.001 vs. metforminAll nateglinide/placebo taken three times daily before meals; all metformin 1000 mg twice daily. Placebo Nateglinide  60 mg Nateglinide  120 mg + + + metformin metformin metformin HbA1C (%)N=150N=152N=154 Baseline (mean) 8.2 8.0 8.2 Change from baseline (mean) 0.01 -0.4 -0.6 Difference from metformin -0.4a -0.6b

14.4 Add-On Combination Therapy With Rosiglitazone

A 24-week, double blind, multicenter, placebo-controlled trial was performed in patients with type 2 diabetes not adequately controlled on rosiglitazone 8 mg daily. The addition of nateglinide (120 mg three times per day with meals) was associated with statistically significantly greater reductions in HbA1C compared to placebo as add-on to rosiglitazone. The mean change in weight from baseline was +3 kg for patients treated with nateglinide compared to +1 kg for patients treated with placebo when added to rosiglitazone. Table 9 Endpoint results for a 24-week study of the effect of adding Nateglinide or placebo to rosiglitazone Placebo + Nateglinide 120 mg before meals + rosiglitazone 8 mg once daily rosiglitazone 8 mg once daily HbA1C (%)N=191N=194 Baseline (mean) 8.4 8.3 Change from baseline (mean) 0.03 -0.7 Difference from rosiglitazone (mean) -0.7aap-value ≤ 0.0001

14.5 Add-On Combination Therapy With Glyburide

In a 12-week study of patients with type 2 diabetes inadequately controlled on glyburide 10 mg once daily, the addition of  nateglinide (60 mg or 120 mg three times daily before meals) did not produce any additional benefit. Table 10 Endpoint results for a 12-week study of the effect of adding Nateglinide or placebo to glyburide Placebo or nateglinide given 10 minutes prior to breakfast, lunch, and dinner; glyburide given with the breakfast dose of nateglinide or placebo.ap-value 0.6959bp-value 0.1246 Placebo + Nateglinide 60 mg before meals + Nateglinide 120 mg before meals + glyburide 10 mg once daily glyburide 10 mg once daily glyburide 10 mg once daily HbA1C (%)N=58N=55N=54 Baseline (mean) 8.7 8.7 8.7 Change from baseline (mean) 0.3 0.2 -0.02 Difference from glyburide (mean) -0.1a -0.3b

16 How Supplied/Storage And Handling

How SuppliedNateglinide Tablets USP, 60 mg are white to off-white, round, biconvex with bevel-edge,film-coated tablets debossed '721' on one side and plain on the other side and are supplied as follows:NDC 70771-1015-3 in bottle of 30 tabletsNDC 70771-1015-9 in bottle of 90 tabletsNDC 70771-1015-1 in bottle of 100 tabletsNDC 70771-1015-5 in bottle of 500 tabletsNDC 70771-1015-0 in bottle of 1000 tabletsNDC 70771-1015-4 in unit-dose blister cartons of 100 (10 x 10) unit dose tabletsNateglinide Tablets USP, 120 mg are light-orange to orange, oval, biconvex with bevel-edge, film-coated tablets debossed '722' on one side and plain on the other side and are supplied as follows:NDC 70771-1016-3 in bottle of 30 tabletsNDC 70771-1016-9 in bottle of 90 tabletsNDC 70771-1016-1 in bottle of 100 tabletsNDC 70771-1016-5 in bottle of 500 tabletsNDC 70771-1016-0 in bottle of 1000 tabletsNDC 70771-1016-4 in unit-dose blister cartons of 100 (10 x 10) unit dose tabletsStorage  and HandlingStore at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense in tightly closed container.

17 Patient Counseling Information

AdministrationInstruct patients to take nateglinide tablets 1 to 30 minutes before meals. Instruct patients that skip meals to skip their dose of nateglinide tablets [see Dosage and Administration (2)].HypoglycemiaInform patients that nateglinide tablets can cause hypoglycemia and instruct patients and their caregivers on self-management procedures including glucose monitoring and management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended [see Warnings and Precautions (5.1)].Drug InteractionsDiscuss potential drug interactions with patients and inform them of potential drug-drug interactions with nateglinide tablets.

Other

Manufactured by:Cadila Healthcare Ltd.Ahmedabad, IndiaRev.:07/17

* Please review the disclaimer below.